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esponsibility of InstAbstract The aim of this study was to develop a formulation to improve the oral absorption of baicalin
(BA) by combining a phospholipid complex (PC) and self-emulsifying microemulsion drug delivery
system (SMEDDS), termed BA–PC–SMEDDS. BA–PC was prepared by a solvent evaporation method
and evaluated by complexation percentage (CP). The physicochemical properties of BA–PC were
determined. The synergistic effect of PC and SMEDDS on permeation of BA was studied in vitro with
Caco-2 cells and in situ with a single pass intestinal perfusion model. The improved bioavailability of BA
in BA–PC–SMEDDS was conﬁrmed in an in vivo rat model. The CP of BA–PC reached 100% when the
molar ratio of drug to phospholipid (PP) was Z1:1. The solubility of BA–PC increased in both water and
octanol, and the log Po/w of BA–PC was increased signiﬁcantly. BA–PC–SMEDDS could be dispersed
more evenly in water, compared to BA and BA–PC. Both the Caco-2 cell uptake and single-pass intestinal
perfusion models illustrated that transport of BA in BA–PC was lower than that of free BA, while2
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Figure 1 The chemical
H. Wu et al.218improved signiﬁcantly in BA–PC–SMEDDS. The relative bioavailability of BA–PC(1:2)–SMEDDS was
220.37%. The combination system of PC and SMEDDS had a synergistic effect on improving the oral
absorption of BA.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Baicalin (BA, 5,6-dihydroxy-4-oxygen-2-phenyl-4H-1-benzopyran-7-
β-D-glucopyranoseacid), as shown in Fig. 1, is a major ﬂavonoid
component extracted from the rhizomes of the traditional Chinese
medicinal herb Scutellaria baicalensis Georgi. BA has been reported to
possess a wide range of pharmacological and biological effects
including anti-inﬂammatory1,2, anti-endotoxin3, anti-allergic4, antimi-
crobial5, antioxidant6,7, antiproliferative8,9 and anti-tumor10,11 actions.
The clinical applications of BA include the treatment of pneumonia,
hepatitis, cardiovascular diseases and cancer11–13. Because of low oral
bioavailability14, various formulations have been developed to improve
the gastrointestinal (GI) absorption of BA. Solid dispersions15, micro-
capsules16,17, cyclodextrins18, emulsions19, phospholipid complex20,
liposomes21 and nanoparticles22 have been described. Based on the
extremely low hydrophilicity (solubility 0.052 mg/mL in water) and
lipophilicity (Papp¼0.037 106 cm/s), BA may be classiﬁed as a
class IV compound according to Biopharmaceutical Classiﬁcation
System (BCS).
Recently, complexes of phospholipid with various poorly
absorbed compounds have been explored to improve the bioavail-
ability of orally administered drugs. Phospholipid complex (PC) is
obtained by the interaction of natural or synthetic phospholipids
(PP), such as phosphatidylcholine, phosphatidylethanolamine or
phosphatidyiserine with the selected botanical derivatives at an
appropriate ratio in an aprotic solvent23. Since PP is a component of
biological membranes24 and can alter the hydrophobicity of a drug
after formation of the PC, it is hypothesized that the formation of a
drug-PC could increase the permeation of drugs across membranes.
Previous studies suggested that the oral bioavailability of poorly
absorbed phytoconstituents can be improved by using PC drug
delivery systems25–27. Although PC may signiﬁcantly increase
membrane transport, the higher lipophilicity of PC led to a poorer
dispersion in aqueous media including GI ﬂuid, as determined in a
preliminary study by our group.structure of BA.When the size of oil droplets is reduced to a nanometer scale,
formulating a low aqueous solubility drug into an emulsion dosage
form is an effective method to increase the surface area of the
dispersed phase that contains poorly water soluble drugs. Self-
emulsifying microemulsion (SMEDDS, size of oil droplets
o500 nm) can be formed with a low-energy requirement under such
conditions as gentle agitation or even gastric mobility28–30. SMEDDS
can enhance drug absorption via improved dissolution and diffusion,
facilitated intestinal lymphatic transport of drugs, protection against
enzymatic hydrolysis31 and inhibition of efﬂux by P-glycoprotein (P-
gp)32. This method has been shown to be effective for BCS II drugs,
e.g., silymarin, oridonin and curcumin33–35. Although SMEDDS has
been reported to increase the bioavailability of many drugs by
increasing water solubility, the increase in bioavailability of BCS IV
compounds using SMEDDS is limited.
The objectives of this study were to design a delivery system
that will take advantage of both PC and SMEDDS to improve the
absorption of BA in the GI and probe the mechanisms of
bioavailability enhancement by characterizing the solubility and
partition coefﬁcients as well as investigating the change in
lipophilicity after formation of PC. In vitro cell permeation,
in situ single-pass intestinal perfusion (SPIP) and in vivo bioavail-
ability studies were conducted to demonstrate the effect of the
BA–PC–SMEDDS system on bioavailability enhancement.2. Materials and methods
2.1. Materials and animals
Baicalin was purchased from Xi'an Xiaocao Plant Technology Co.,
Ltd. (Xi'an, China; purity: 98%). Lipoid S75 was supplied by
Shanghai Dongshang Biological Technology Co., Ltd. (Shanghai,
China). Puriﬁed ovolecithin was obtained from Guangzhou
HanFang Modern Traditional Chinese Medicine Research Co.,
Ltd. (Guangdong, China). Caco-2 cells were a generous gift from
the Laboratory of Dr. Huang at the School of Pharmaceutical
Sciences, Sun Yat-Sen University (Guangdong, China). Ethyl
oleate and glycerol (molecular biology grade) were purchased
from Aladdin Reagent Co., Ltd. (Shanghai, China). Tween-80
was supplied by Shanghai ShenYu Pharmaceutical and Chemical
Industry Co., Ltd. (Shanghai, China). Tetrahydrofuran was pur-
chased from Tianjin Zhiyuan Chemical Reagents Co., Ltd.
(Tianjin, China). Methanol, n-octanol, isopropanol, anhydrous
ethanol and potassium dihydrogen phosphate were purchased
from Tianjin Damao Chemical Reagent Factory (Tianjin, China).
Sodium hydroxide and concentrated hydrochloric acid were
obtained from Tianjin Baishi Chemical Co., Ltd. (Tianjin, China).
Hanks' Balanced Salt Solution (HBSS) solution was obtained from
Hangzhou Gino Bio-pharmaceutical Technology Co., Ltd. (Zhe-
jiang, China). High purity liquid nitrogen was purchased from
Guangzhou Junduo Gas Co., Ltd. (Guangdong, China). Acetoni-
trile and methanol (HPLC grade) were purchased from Dikma
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solvents used in this study were of analytical grade.
Sprague-Dawley rats weighing 200720 g were purchased from
the Animal Center of Guangdong Medical Laboratory (Guangdong,
China). The protocol for animal experiments was approved by the
Guangdong Pharmaceutical University Experimental Animal Ethics
Committee.2.2. Preparation of BA–PC
BA–PC was prepared according to a previously published
method36 with modiﬁcations. Brieﬂy, BA and PP at molar ratios
of 1:0.5, 1:1, 1:1.5 and 1:2 were added in a 50 mL conical ﬂask
with tetrahydrofuran (1 mg of BA/0.2 mL) as solvent. The
suspension was sonicated for 15 min and maintained at 45 1C
with stirring in a water bath for 0.5 h to dissolve the drug and form
the complex. Tetrahydrofuran was evaporated under vacuum at
40 1C using a rotary vacuum evaporator. The dried residues were
placed in a sealed vial and kept at 4 1C. The molar ratio of BA and
PP in the complexes was determined by complexation percentage
(CP) of BA, using the following equation:
CPð%Þ ¼ ab
a
 100% ð1Þ
where a is the initial weight of BA, b is the weight of free BA in
BA–PC. The weight of free BA in BA–PC was measured
according to the difference of solubility among BA, BA–PC and
PP in chloroform, i.e., both BA–PC and PP can dissolve in
chloroform, but free BA was insoluble in chloroform. The
precipitate of BA in chloroform was dissolved in methanol and
analyzed by using a UV spectrophotometer at 316 nm.2.3. Determination of solubility and apparent oil–water
partition coefﬁcient
The solubility of BA and BA–PC was determined by adding an
excess of BA or BA–PC to a vial containing 5 mL of water or
octanol. The vials were sealed and placed in a water bath shaker at
37 1C for 48 h with continuous shaking at 100 rpm. The suspen-
sions were then ﬁltered with 0.22 μm ﬁlter immediately at the
same temperature to remove the insoluble substances. The con-
centrations of BA in the ﬁltrate were determined by a UV
spectrophotometry. Three replicate analyses were carried out for
each formulation, and the data are presented as means7SD.
The apparent oil–water partition coefﬁcient (Po/w) was obtained
using the method described previously37,38. Solutions of BA or
BA–PC (BA 50 μg/mL) were prepared in water-saturated octanol.
These solutions were then equilibrated at 37 1C with an equal
volume (5 mL) of octanol-saturated water using a magnetic stirrer
at 700 rpm for 24 h. The phases were then separated by centrifu-
gation. The total drug concentration in water-saturated octanol
before equilibration and that in the octanol phase after separation,
Ctotal and Co, respectively, were determined using a UV spectro-
photometer as described above. The concentration of drug in the
aqueous phase, Cw, was obtained from the mass balance (Cw¼
Ctotal–Co). Experiments were performed in triplicate to assess
reproducibility and data were presented as means7SD. Po/w was
calculated using the following equation:
Po=w ¼
Co
Cw
ð2Þwhere Co is the concentration of BA in octanol and Cw is the
concentration of BA in water.
2.4. Dispersible uniformity and stability of BA–PC and BA–PC–
SMEDDS
For the current study, a pre-microemulsion concentrate (PMC) of
SMEDDS developed previously in our lab was used. Ethyl oleate,
Tween-80 and glycerol (weight ratio of 1:2.25:1.75) were mixed at
ambient temperature and loaded with BA–PC (equivalent to 75 mg
of BA) at different drug to PP molar ratio of 1:1, 1:1.5 or 1:2. The
mixtures were heated at 65 1C in a water bath and stirred mildly to
get PMC.
The microemulsion was formed spontaneously by adding PMC
dropwise to 100 mL of distilled water in a wide-mouth bottle under
gentle stirring for two minutes at 37 1C in a water bath. BA–PC
was dispersed in water by sonication. Free BA was dispersed in
water by a simple agitation. All samples were maintained at 37 1C
in a water bath. The concentration of BA in the upper solution was
determined at 316 nm by UV spectrophotometry at 0, 4, 8, 12 and
24 h.
2.5. Caco-2 cell permeation studies of BA, BA–PC and BA–PC–
SMEDDS
Transepithelial permeation studies were performed using a previously
described method39–41. The Caco-2 cells were cultured in Dulbec-
co's Modiﬁed Eagle Medium (DMEM) containing 4.5 mg/mL
glucose, 10% FCS, 1% nonessential amino acids, 1% sodium
pyruvate, 1% glutamine, and 1% penicillin/streptomycin under 5%
CO2 and 95% relative humidity at 37 1C. When the conﬂuency
reached 80% the cells were seeded at the density of 2 105 cells/cm2
onto the membranes of Transwell inserts coated with type-I
collagen (12-well Transwell plate, 0.4 mm pore size, 12 mm
diameter, 1.12 cm2 area, Corning Display Technologies (China)
Co., Ltd.) and cultured for 21 days in DMEM. The medium was
replaced every 48 h for the ﬁrst 6 days and every 24 h thereafter.
The integrity of the cell layer was evaluated by measuring the
transepithelial electrical resistance (TEER) using Millicell-ERS
(Millipore Corporation, Bedford, MA) before and after each
transport experiment. Permeation studies were conducted when
TEER value was greater than 250 Ω  cm2.
Prior to the permeation experiment, the media on both sides of
transwell monolayers were replaced 3 times with HBSS and then
equilibrated for 30 min. The medium of the apical-side was
removed and replaced with 0.5 mL of the test solutions (pH 6.8,
37 1C) containing BA at different concentrations (375 μg/mL,
281.2 μg/mL and 187.5 μg/mL), BA–PC or BA–PC–SMEDDS
at different drug to PP molar ratios of 1:1, 1:1.5 and 1:2 containing
187.5 μg/mL of BA. The basolateral side contained 1.5 mL of
HBSS. The transport plates were kept at 37 1C in a shaking
incubator at 50 rpm. Samples (100 μL) were taken from the
basolateral side at 30, 60, 90, 120 and 180 min. An equal volume
of the fresh HBSS was added following each sample withdrawal.
The collected samples were centrifuged at 14,000 rpm for 10 min
and the concentration of BA was analyzed by using an HPLC
system (Waters 1525 HPLC pump, 2489 UV detector, Milford,
USA) at 270 nm with a C18 column (Platisil, 250 mm 4.6 mm,
5 μm). A mixture of acetonitrile and water (27:73) which contains
0.035% of triethylamine and 0.025% of phosphoric acid was used
as a mobile phase. The ﬂow rate was set at 1 mL/min.
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by adding 0.5 mL of HBSS to the apical side and 1.5 mL of the
test solutions to the basolateral side. Other procedures were
performed as described in the apical to basolateral studies. Free
BA solution (187.5 μg/mL) was prepared with HBSS containing
100 μg/mL of verapamil, a P-gp inhibitor, to study apical-to-
basolateral and basolateral-to-apical transports using the same
procedures. The cumulative permeation quantity (Q, μg), apparent
permeability coefﬁcients (Papp, cm/s) and efﬂux ratio (ER) were
calculated using Eqs. (3)–(5), correspondingly.
Q¼CnV1 þ ∑
n1
m ¼ 1
CmV2 ð3Þ
where Cn is the drug concentration in the receiver compartment at
the nth time point (μg/mL), ∑n1m ¼ 1Cm represents the cumulative
concentration from the ﬁrst to the (n1)th time point (μg/mL)
which corrects for the withdrawn samples, and V1 and V2
correspond to the volumes of the receptor compartment and the
collected samples at each time point (mL), respectively.
Papp ¼
dQ
dt
 1
AC0
ð4Þ
where dQ/dt is the steady-state ﬂux (μg/min) of drug, which is
obtained from the slope of the linear regression of cumulative
transport amount versus time curve, C0 is the initial concentration
in donor chamber (μg/mL), and A is the surface area of the
monolayer (cm2).
ER¼ PappðBAÞ=PappðABÞ ð5Þ
where Papp(BA) is the permeability coefﬁcient determined by the
transport of drug from the basal to the apical compartment, and
Papp(AB) is that from the apical to the basal direction.
Data are reported as means7SD, n¼3 for individual groups.
The unpaired Student's t-test was used to determine statistical
signiﬁcance by using ANOVA of JMPs, version10.0.0 software
(SAS Institute Inc., USA) and P values of less than 0.05 were
considered signiﬁcant.
2.6. Single-pass intestinal perfusion studies of BA, BA–PC and
BA–PC–SMEDDS
Sprague-Dawley rats weighing 200720 g were used in the
perfusion studies. Prior to the experiments, the animals were
fasted overnight for at least 12 h with free access to water. The rats
were randomly assigned to ﬁve experimental groups.
The procedure for the SPIP experiment was taken from the
previous literature42–45. Rats were anaesthetized by an intraper-
itoneal injection of 6 mL/kg urethane (10% w/v) and placed on a
plank and kept warm with a table lamp. The abdomen was opened
using a longitudinal incision of 3–4 cm along the midline. After
the small intestine was carefully exposed, a 10 cm segment of
intestine (including duodenum and jejunum, ileum, and colon) was
cannulated at both ends with ﬂexible PVC tubing (2.29 cm, i.d.)
and ligated using silk thread. The exposed segment was kept moist
with 37 1C saline solution. Krebs–Ringer (KR) buffer was used
as perfusate, which consisted of NaCl, 7.8 g/L; KCl, 0.35 g/L;
CaCl2, 0.37 g/L; NaH2PO4, 0.22 g/L; NaHCO3, 1.37 g/L; MgCl2,
0.22 g/L; and glucose, 1.4 g/L, and adjusted to pH 6.0 using
phosphoric acid. Test solutions used in the perfusion study were
prepared by dissolving BA, BA–PC or BA–PC–SMEDDS at drug
to PP molar ratios of 1:1 and 1:2 in KR buffer at a 750 μg/mL ﬁnal
concentration of BA. The intestinal segments were gently rinsedwith a blank KR solution to remove intestinal contents. The test
solution was infused by a circulation pump at a ﬂow rate of
1.0 mL/min for 10 min followed by adjustment to 0.2 mL/min for
30 min to reach the steady-state condition. When the concentration
ratio of phenol red ('non-absorbed' marker) between inlet and
outlet approached one, the outﬂow perfusate was collected at a
15 min interval for 150 min. Concentrations of phenol red and BA
were analyzed by the same HPLC method as described in Section
2.5. The length of the small intestine segment was measured after
the ﬁnal collection.
The absorption of water was corrected by phenol red concen-
tration at inlet and outlet using46.
CoutðcorrectedÞ ¼
CoutCPRðinÞ
CPRðoutÞ
ð6Þ
where Cout is the drug concentration measured in the outlet
perfusate, CPR(in) and CPR(out) are the concentrations of phenol
red at inlet and outlet, respectively. The effective permeability
(Peff) was calculated using
Peff ¼
Q lnðCin=CoutðcorrectedÞÞ
2πRL
ð7Þ
where Cout(corrected) is the corrected drug concentration in the
outlet perfusate at the steady state, Cin is the drug concentration at
the inlet, Q is the perfusion ﬂow rate (0.2 mL/min), L is the length
of intestinal segment (cm), and R is the radius of intestinal segment
(cm). Statistical analysis was carried out as described in Section
2.5.
2.7. Oral bioavailability of BA–PC–SMEDDS and BA
suspensions
Rats were fasted overnight for at least 12 h before dosing, with
free access to water throughout the experiments. Twelve male and
female Sprague-Dawley rats weighing 200720 g were divided
randomly into two groups of six each with the equal number of
male and female. The rats in each group were gavaged with 5 mL
of BA or BA–PC(1:2)–SMEDDS dispersed in water, each contain-
ing 75 mg of BA. Under ether anesthesia, 0.3 mL of blood samples
were collected through the orbital vein prior to dosing and at the
predetermined time of 0.167, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0
and 12.0 h post-dosing. The blood samples were collected in
polypropylene tubes with heparin, and then centrifuged immedi-
ately at 3500 rpm for 15 min to obtain plasma. The plasma was
mixed with 0.25 mL of 10% of perchloric acid–methanol solution
and mixed for 3 min using a XW-80A vortex mixer to precipitate
protein47. The suspension was centrifuged at 3500 rpm for 15 min
and the supernatant was analyzed by HPLC with the same
chromatographic conditions as described in Section 2.5 to deter-
mine the concentration of BA.
The biopharmaceutical and pharmacokinetic parameters, i.e.,
maximum peak concentration (Cmax), time to reach Cmax (Tmax),
area under plasma time curve (AUC) were obtained by using
WinNonlin, version 6.1 (Pharsight, A Certara™ Company, USA),
noncompartmental analysis. The relative bioavailability (Fr) was
calculated using
Fr ¼
AUCT
AUCR
 100% ð8Þ
where AUCT refers to the area under plasma time curve of test
formulation and AUCR refers to the area under plasma time curve
of control. Experimental values are expressed as mean7SD.
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version 10.0.0 software (SAS Institute Inc., USA) and the data
were considered statistically signiﬁcant at Po0.01.Figure 2 The concentration change of BA in the upper solution part
of water over time when BA, BA–PC, BA–PC–SMEDDS were
dispersed in water at 37 1C. Data are expressed as mean7SD (n¼3).
Figure 3 Particle size of BA–PC–SMEDDS.
Table 2 Apparent permeability coefﬁcients (Papp) and efﬂux
ratio (ER) of BA with or without verapamil.
Formulation Papp ( 106, cm/s)a ER
AP–BL BL–AP
BA 0.11970.092 0.36570.096 3.067
BAþverapamil 0.62270.101n 0.17470.000n 0.280
aData were expressed as mean7SD, n¼3.
nPo0.05 compared to BA.3. Results and discussion
3.1. Complexation percentage, solubility and oil–water partition
coefﬁcient of BA–PC
At different drug to PP molar ratios, the CP (%), solubility and Po/w of
BA and BA–PC in water and octanol are shown in Table 1. The CP
(%) reached 100% when molar ratio of drug to PP was above 1:1.
Though BA–PC increased the solubility of BA in water and octanol,
the improvement of solubility in octanol was more signiﬁcant than that
in water. When the molar ratio of BA to PP was increased from 1:1 to
1:2, the solubility of BA–PC increased 48–85 times in octanol which
made log Po/w increase from 1.03 to 0.105, 0.024 and 0.18,
correspondingly, compared with BA.
It is generally known that most drugs cross the lipid-rich epithelial
cells of the small intestine by passive diffusion and high solubility
and high permeability are important for a high bioavailability. Thus,
it is an effective method to increase bioavailability of BA by
improving its water solubility and bioﬁlm permeability. Po/w has
been associated with the biomembrane permeability of drugs; drugs
with a log Po/w in a range between 1 and 248 have been shown to
have good oral absorption. When log Po/w is lower than 1 or higher
than 2, drug absorption tends to be lower due to the poor permeability
or poor partition between biomembrane and intracellular ﬂuid. The
data in Table 1 revealed that log Po/w of BA–PC at different BA to
PP molar ratios was within the optimal range contrary to that of BA,
and 1:2 was better than 1:1 and 1:1.5.
3.2. Dispersible uniformity and stability in water
Even though the high log Po/w of BA–PC may improve the
permeability of BA, the data in Table 1 illustrated BA–PC
increased the solubility of BA in water slightly and BA–PC could
not be dispersed homogeneously in water (Fig. 2). When BA was
dispersed in water, the concentration of BA in the upper solution
was nearly zero initially (solid rhombus in Fig. 2). For BA–PC, the
concentrations of BA decreased to 30%–60% of the original
concentration at different molar ratios of BA to PP (1:1 (solid
round), 1:1.5 (solid triangle) and 1:2 (solid square)) after 24 h at
37 1C. But the concentrations of BA remained above 80% of the
original concentration for BA–PC–SMEDDS (1:1, 1:1.5, 1:2,
opening shape in Fig. 2) with a particle size of about 228 nmTable 1 The complexation percentage (CP), solubility and apparent
Formulation Molar ratio of BA to PP CP (%) Solubi
Water
BA — N/A 0.0527
BA–PC 1:0.5 80 N/A
1:1 100 0.0927
1:1.5 100 0.1297
1:2 100 0.1577
aData were expressed as mean7SD, n¼3.
nPo0.05 compared to BA. N/A, no data available.(Fig. 3). Visually, the precipitates of free BA and BA–PC at molar
ratios of BA to PP 1:1 and 1:1.5 were found at the bottom of the
bottles, but there was very little precipitate for BA–PC at molar
ratio of BA to PP 1:2 and all BA–PC–SMEDDS. In water, BA
possibly dissociated from BA–PC when the hydrogen bonding
force between BA and water was greater than that between BA andoil–water partition coefﬁcient (log Po/w) in various formulations.
lity of BA (mg/mL)a log Po/w (37 1C)
a
Octanol
0.0015 0.13670.012 1.03270.014
N/A N/A
0.0066 6.54270.96n 0.10570.005
0.0028 9.06570.76n 0.02470.009
0.0003 11.6871.13n 0.18270.006
H. Wu et al.222PP, leading to a decrease in the concentration of BA in the upper
solution part and the formation of precipitates at low molar ratio of
BA to PP. There were no precipitates for BA–PC at 1:2 M ratio of
BA to PP because of the strong hydrogen bonding at a high molar
ratio of BA to PP. However, the concentration decrease in BA in
the upper solution was very limited for all BA–PC–SMEDDS.
This may be attributed to the oil in SMEDDS which weakens the
hydrogen bonding force between BA and water while surfactants
can facilitate the dispersion of BA–PC. Therefore, the concentra-
tion reduction of BA in water may be related not only to theTable 3 Apparent permeability coefﬁcients (Papp) through
Caco-2 monolayer of BA, BA–PC and BA–PC–SMEDDS at
various molar ratios of drug to PP.
Formulation Papp ( 106, cm/s)
BA 0.03770.012
BA–PC(1:1) 0.04570.012
BA–PC(1:1.5) 0.02470.008
BA–PC(1:2) 0.01770.002n
BA–PC(1:1)–SMEDDS 0.32870.036n
BA–PC(1:1.5)–SMEDDS 0.69070.057n
BA–PC(1:2)–SMEDDS 0.77470.084n
Data were expressed as mean7SD, n¼3.
nPo0.05 compared with BA.
Figure 4 Cumulative permeation quantity (a) and apparent permeabili
concentrations. Data were expressed as mean7SD (n¼3).
Figure 5 Comparison of cumulative permeation quantity (Q) through a
SMEDDS (b) at various molar ratios of drug to PP. Data were expressednonuniform dispersion of BA–PC but also to the poor stability
caused by the dissociation of BA from BA–PC.3.3. In vitro permeation through Caco-2 cell model
As shown in Fig. 4a, Q was increased with an increase in the
concentration of BA, and Papp was almost the same at correspond-
ing concentrations (P40.05) as shown in Fig. 4b. The data
suggest the passive diffusion mechanism of BA transport. It is
obvious from Table 2 that the presence of verapamil signiﬁcantly
increased the A-B permeation (Po0.05) and reduced the B-A
efﬂux (Po0.05), causing a decrease in ER from 3.067 to 0.280.
These results suggest that BA may be a substrate of P-gp which
partly explains the low biomembrane permeability of BA and
SMEDDS formulations containing Tween 80, a P-gp inhibitor, to
decrease efﬂux of P-gp49,50.
The transcellular transport of BA–PC and BA–PC–SMEEDS
across the Caco-2 monolayer compared with that of free BA is
shown in Fig. 5 and Table 3. The Q and Papp of BA–PC were
lower than that of free BA and decreased following the increase in
the molar ratio of BA to PP (Fig. 5a and Table 3), though the Papp
at 1:1 M ratio of BA to PP was a little higher than that of BA. In
theory, PC could promote the biomembrane permeation of BA by
high log Po/w, and the reason why the Q of BA–PC was lower than
that of free BA could be explained from the data in Table 1 and
Fig. 2. PC increased the solubility of BA in water only 1.7-fold butty coefﬁcients (b) of BA through a Caco-2 monolayer at different
Caco-2 monolayer between BA and BA–PC (a), BA and BA–PC–
as mean7SD (n¼3).
Combined use of phospholipid complexes and self-emulsifying microemulsions 22348-fold in octanol when molar ratio of BA to PP was 1:1. Too high
lipophilicity reduced the dispersion uniformity of BA–PC in buffer
because of the special structure51 (shown in Fig. 6) of PP. When
the polar groups of PP such as positive choline group or negative
phosphate group bond with the polar group of the drug by
hydrogen bonds to form complex, the charges of PC were
neutralized and entrapped easily by two lipophilic tails of PP.
The comparison of Papp between BA and BA–PC demonstrates
that appropriate balance between lipophilicity and hydrophilicity is
very important for biomembrane transport.
The disadvantage of PC was remedied by the use of SMEDDS
which facilitated a better dispersibility of BA–PC–SMEDDS in
buffer. The Q and Papp of BA–PC–SMEDDS were signiﬁcantly
higher than that of BA (Figure 5b and Table 3) and increased with
increasing molar ratio of BA to PP after 90 min. Since the toxicity
of surfactant in SMEDDS was monitored by MTT and TEER and
the data showed that the cell viability and integrity did not change
signiﬁcantly during the experiment (data not shown), the results
presented in Fig. 5b and Table 3 show that the permeation of BA
was markedly enhanced by PC–SMEDDS. In addition, SMEDDS
itself can enhance the permeation of drugs. Thus, it also indicated
that PC and SMEDDS had synergistic effects for improving the
biomembrane transport of BA. The bioavailability of drug is
greater than 1% but less than 100% in humans if the permeability
coefﬁcients are in the range of 0.1 106–1.0 106 cm/s in
Caco-2 cell52, so BA–PC–SMEDDS, especially BA–PC(1:2)–
SMEDDS (Papp¼ (0.77470.084) 106 cm/s) might have good
oral absorption.Figure 6 Schematic diagram of PC.
Table 4 Effects of BA–PC and BA–PC–SMEDDS at different molar
intestine segments.
Formulation BA:PP Peff ( 104, cm
Duodenumþjeju
BA – 0.13970.035n
BA–PC 1:1 0.07870.021n,#
1:2 0.12970.019n
BA–PC–SMEDDS 1:1 0.15970.034n
1:2 0.51370.040n,#
aData were expressed as mean7SD, n¼6.
nPo0.05 compared to colon.
#Po0.05 compared to BA.The reason why there was no signiﬁcant difference of Q
between BA and BA–PC–SMEDDS in the ﬁrst 90 min
(P40.05) might be explained in terms of the release of BA
needed to overcome the intermolecular forces between BA and PP.
Although Tween 80 in the BA–PC–SMEDDS formulation was a
P-gp inhibitor, there might be less contact area between SMEDDS
and the cells at ﬁrst, resulting in BA, as the substrate of P-gp
described above, showing an apparent increase in efﬂux in the ﬁrst
90 min.3.4. Single-pass intestinal perfusion
From the in vitro Caco-2 monolayer permeation study, we have
demonstrated that BA–PC–SMEDDS could increase the Papp of
BA. Since the SPIP approach in rats had been shown to be a
precise method to predict in vivo oral absorption in man, this
model was used to verify further the results from Caco-2 cells.
The data in Table 4 depicted the SPIS results of BA–PC and BA–
PC–SMEDDS at lowest and highest molar ratios of BA to PP (e.g., 1:1
and 1:2). The Peff of BA in colon was signiﬁcantly (Po0.05) higher
than in the other intestinal segments, followed by the ileum and upper
intestinal site (including duodenum and jejunum). The highest Peff of
BA in the colon suggested that colon was the main absorption site, and
did not change with the formation of BA–PC and BA–PC–SMEDDS.
The Peff of BA–PC and BA–PC–SMEDDS had the same tendencyratios on effective permeability coefﬁcients (Peff) of BA in different
/s)a
num Ileum Colon
0.25270.081n 0.50670.088
0.15270.033n 0.50470.075
0.29770.054n 0.45670.033
0.58370.099n,# 1.45970.235#
1.17370.119n,# 2.22970.284#
Figure 7 Plasma concentration–time proﬁles of BA in rats after oral
administration BA and BA–PC(1:2)–SMEDDS. Data were expressed
as mean7SD (n¼6).
Table 5 Pharmacokinetic parameters in rats after oral administration of BA and BA–PC(1:2)–SMEDDS.
Formulation Tmax (h) Cmax (μg/mL) AUC (μg  h/mL) Fr (%)
BA 1.570.0 1.8470.47 7.6171.58 220.37749.93
BA–PC(1:2)–SMEDDS 2.070.0n 3.7471.15nn 17.2873.62nn
Data were presented as mean7SD, n¼6.
nPo0.05 compared to BA group.
nnPo0.01 compared to BA group.
H. Wu et al.224with Caco-2 cells, i.e., PC did not facilitate the permeation of BA, but
the permeation of BA could be enhanced signiﬁcantly by PC–
SMEDDS. The Peff of BA–PC–SMEDDS increased noticeably in all
the segments except BA–PC(1:1)–SMEDDS in duodenum and
jejunum (non-main absorption site) (Po0.05), compared to that of
free BA. Moreover, when the Peff40.42 104 cm/s53,54, the drug
could be considered well absorbed in human. Therefore, the permea-
tion improvement of BA formulated in PC(1:2)–SMEDDS was
demonstrated further by SPIS.
3.5. Relative oral bioavailability of BA–PC–SMEDDS and BA
suspensions
Taking into consideration of the results from Caco-2 cells and
SPIS, BA–PC(1:2)–SMEDDS, as the optimal formulation, was
used for the oral bioavailability study in vivo and the BA
suspension at the same dose was used to evaluate bioavailability.
Fig. 7 shows the plasma concentration–time proﬁles obtained after
administration of BA suspension and BA–PC(1:2)–SMEDDS. The
pharmacokinetic parameters are shown in Table 5. Signiﬁcant
differences were found for Cmax, Tmax and AUC. The Cmax and
AUC of PC–SMEDDS group were remarkably bigger than those
of free BA group (Po0.01), and relative bioavailability (Fr) was
220.37749.93%. The results suggested that PC–SMEDDS
increased signiﬁcantly the oral absorption of BA in rats. Tmax of
free BA group was smaller than that of BA–PC(1:2)–SMEDDS
group (Po0.01) and might be due to the delayed release of BA
from BA–PC–SMEDDS.
Base on the results above, the present research indicated that the
combination of PC and SMEDDS could improve simultaneously
the solubility in aqueous medium and biomembrane permeation of
BA in vitro as determined from the physical and chemical models,
Caco-2 cells, and SPIS, and the increased oral absorption of BA
from the optimal dosage form of PC–SMEDDS was demonstrated
in the rat in vivo model, which was consistent with in vitro studies.
Therefore, the in vitro model study is very important for drugg-
ability research, especially given the issues of animal ethics, cost,
time and huge candidate compounds. From the in vitro model, the
optimal dosage form of a drug can be designed and veriﬁed
in vivo.4. Conclusions
The synergistic effects of PC and SMEDDS on enhancing the
bioavailability of BA, a BCS class IV compound, have been
studied systematically by in vitro physical and chemical models, a
Caco-2 cell transport model, an in situ SPIP model and in vivo rat
model. Our results may be of important reference value for the oralabsorption of other class IV compound. PC–SMEDDS has a good
balance for lipophilicity and hydrophilicity of drugs which is
critical for oral absorption. Moreover, it is worth noticing that PC–
SMEDDS cannot solve the oral absorption problems associated
with all BCS IV drug. Drugs with a phenolic hydroxyl group
should have a high complexation percentage with PC and good
oral absorption by means of PC–SMEDDS based on the results of
our studies. The correlation between the structure of a drug and
complexation with PC will be reported in the future.Acknowledgments
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